Tumor suppressor genes in breast cancer

Endocrine-Related Cancer

Volumn 6, Issue 3, 1999, Pages 405-419

  Oesterreich, S ^a,b   Fuqua, S A W ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

BREAST CANCER; CELL TRANSFORMATION; GENE ACTIVATION; GENE MAPPING; GENE MUTATION; GENE STRUCTURE; HUMAN; REVIEW; TUMOR SUPPRESSOR GENE;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENES, P53; GENES, RETINOBLASTOMA; GENES, TUMOR SUPPRESSOR; HUMANS; INCIDENCE;

EID: 0032887943     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0060405     Document Type: Review

References (155)

1. Aas T, Borresen AL, Geisler S, Smith-Sorensen B, Johnsen H, Varhaug JE, Akslen LA & Lonning PE 1996 Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine 2 811-814.
2. Adams PD & Kaelin WG Jr 1996 The cellular effects of E2F overexpression. Current Topics in Microbiology and Immunology 208 79-93.
3. Allred DC & Hilsenbeck SG 1998 Biomarkers in benign breast disease: risk factors for breast cancer. Journal of the National Cancer Institute 90 1247-1248.
4. Andersen TI, Gaustad A, Ottestad L, Farrants GW, Nesland JM, Tveit KM & Borresen AL 1992 Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas. Genes, Chromosomes and Cancer 4 113-121.
5. Barak Y, Juven T, Haffner R & Oren M 1993 mdm2 expression is induced by wild type p53 activity. EMBO Journal 12 461-468.
6. Baylin SB, Herman JG, Graff JR, Vertino PM & Issa JP 1998 Alterations in DNA methylation: a fundamental aspect of neoplasia. Advances in Cancer Research 72 141-196.
7. Bebb G, Glickman B, Gelmon K & Gatti R 1997 'At risk' for breast cancer (see comments). Lancet 349 1784-1785.
8. Biggs JR & Kraft AS 1995 Inhibitors of cyclin-dependent kinase and cancer. Journal of Molecular Medicine 73 509-514.
9. Buchkovich K, Duffy LA & Harlow E 1989 The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell 58 1097-1105.
10. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR & Kley N 1995 Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377 646-649.
11. Bullions LC, Notterman DA, Chung LS & Levine AJ 1997 Expression of wild-type alpha-catenin protein in cells with a mutant alpha-catenin gene restores both growth regulation and tumor suppressor activities. Molecular and Cellular Biology 17 4501-4508.
12. Chapman MS & Verma IM 1996 Transcriptional activation by BRCA1 (letter; comment). Nature 382 678-679.
13. Chee M, Yang R, Hubbell E, Berno A, Huang XC, Stern D, Winkler J, Lockhart DJ, Morris MS & Fodor SPA 1996 Accessing genetic information with high-density DNA arrays. Science 274 610-614.
14. Chen Y, Chen CF, Riley DJ, Allred DC, Chen PL, Von Hoff D, Osborne CK & Lee W 1995 Aberrant subcellular localization of BRCA1 in breast cancer. Science 270 789-791.
15. Chen J, Lindblom P & Lindblom A 1998 A study of the PTEN/ MMAC1 gene in 136 breast cancer families. Human Genetics 102 124-125.
16. Clarke AR, Maandag ER, van Roon M, van der Lugt NM, van der Valk M, Hooper ML, Berns A & te Riele H 1992 Requirement for a functional Rb-1 gene in murine development (see comments). Nature 359 328-330.
17. Colditz GA, Willett WC, Hunter DJ, Stampfer MJ, Manson JE, Hennekens CH & Rosner BA 1993 Family history, age, and risk of breast cancer. Prospective data from the Nurses' Health Study (published erratum appears in Journal of the American Medical Association 1993 270 1548) (see comments). Journal of the American Medical Association 270 338-343.
18. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH & Reid BJ 1995 A p53-dependent mouse spindle checkpoint. Science 267 1353-1356.
19. Del Sal G, Ruaro EM, Utrera R, Cole CN, Levine AJ & Schneider C 1995 Gas1-induced growth suppression requires a transactivation-independent p53 function. Molecular and Cellular Biology 15 7152-7160.
20. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW & Old LJ 1979 Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proceedings of the National Academy of Sciences of the USA 76 2420-2424.
21. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C & Levine AJ 1993 Gain of function mutations in p53. Nature Genetics 4 42-46.
22. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS & Bradley A 1992 Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 215-221.
23. Drmanac S, Kita D, Labat I, Hauser B, Schmidt C, Burczak JD & Drmana R 1998 Accurate sequencing by hybridization for DNA diagnostics and individual genomics. Nature Biotechnology 16 54-58.
24. Dryja TP, Rapaport JM, Joyce JM & Petersen RA 1986 Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proceedings of the National Academy of Sciences of the USA 83 7391-7394.
25. Dupont WD & Page DL 1985 Risk factors for breast cancer in women with proliferative breast disease. New England Journal of Medicine 312 146-151.
26. Dupont DW, Pari FF, Hartmann WH, Brinton LA, Winfield AC & Worrell JA 1993 Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer 71 1258-1265.
27. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW & Vogelstein B 1993 WAF1, a potential mediator of p53 tumor suppression. Cell 75 817-825.
28. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, Campos-Torres J & Leder P 1996 Pleiotropic defects in ataxiatelangiectasia protein-deficient mice. Proceedings of the National Academy of Sciences of the USA 93 13084-13089.
29. Fishel R & Wilson T 1997 MutS homologs in mammalian cells. Current Opinion in Genetics and Development 7 105-113.
30. Foster JS & Wimalasena J 1996 Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Molecular Endocrinology 10 488-498.
31. Foster SA, Wong DJ, Barrett MT & Galloway DA 1998 Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Molecular and Cellular Biology 18 1793-1801.
32. Friend SH, Bernards R, Rogelj S, Weinberg RA, Rapaport JM, Albert DM & Dryja TP 1986 A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323 643-646.
33. Fukasawa K, Choi T, Kuriyama R, Rulong S & Vande Woude GF 1996 Abnormal centrosome amplification in the absence of p53. Science 271 1744-1747.
34. Fung YK, Murphree AL, T'Ang A, Qian J, Hinrichs SH & Benedict WF 1987 Structural evidence for the authenticity of the human retinoblastoma gene. Science 236 1657-1661.
35. Garcia I, Brandt D, Weintraub J, Zhou WG & Aapro M 1991 Loss of heterozygosity for the short arm of chromosome 11 (11p15) in human milk epithelial cells immortalized by microinjection of SV40 DNA. Cancer Research 51 294-300.
36. Garcia-Patino E, Gomendio B, Provencio M, Silva JM, Garcia JM, Espana P & Bonilla F 1998 Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations. Journal of Clinical Oncology 14 115-120.
37. Goodrich DW & Lee WH 1993 Molecular characterization of the retinoblastoma susceptibility gene. Biochimica et Biophysica Acta 1155 43-61.
38. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, Joslyn G, Stevens J, Spirio L, Robertson M et al. 1991 Identification and characterization of the familial adenomatous polyposis coli gene. Cell 66 589-600.
39. Grundy P 1997 Molecular basis of Wilms' tumor. Cancer Treatment and Research 92 101-123.
40. Gualberto A, Aldape K, Kozakiewicz K & Tlsty TD 1998 An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. Proceedings of the National Academy of Sciences of the USA 95 5166-5171.
41. Hacia GH, Brody LC, Chee MS, Fodor SPA & Collins FS 1996 Detection of heterozygous mutations in BRCA1 using high-density oligonucleotide arrays and two color fluorescence analysis. Natural Genetics 14 441-447.
42. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, Hakem A, Wakeham A, Potter J, Reitmair A, Billia F, Firpo E, Hui CC, Roberts J, Rossant J & Mak TW 1996 The tumor suppressor gene BRCA1 is required for embryonic cellular proliferation in the mouse. Cell 85 1009-1023.
43. Hakem R, de la Pompa JL, Elia A, Potter J & Mak TW 1997 Partial rescue of BRCA1 (5-6) early embryonic lethality by p53 or p21 null mutation. Nature Genetics 16 298-302.
44. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B & King MC 1990 Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 1684-1689.
45. Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD & Jirtle RL 1996 M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 12 2003-2009.
46. Harper JW, Adami GR, Wei N, Keyomarsi K & Elledge SJ 1993 The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75 805-816.
47. Haupt Y, Maya R, Kazaz A & Oren M 1997a Mdm2 promotes the rapid degradation of p53. Nature 387 296-299.
48. Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K & Oren M 1997b p53 mediated apoptosis in HeLa cells: transcription-dependent and -independent mechanisms. Leukemia 11 337-339.
49. Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD & Kim DH 1997 ONYX-015, an E1B gene-attenuated adenovifus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (see comments). Nature Medicine 3 639-645.
50. Helin K, Lees JA, Vidal M, Dyson N, Harlow E & Fattaey A 1992 A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 70 337-350.
51. Hengst L & Reed SI 1998 Inhibitors of the Cip/Kip family. Current Topics in Microbiology and Immunology 227 25-41.
52. Hollstein M, Sidransky D, Vogelstein B & Harris CC 1991 p53 mutations in human cancers. Science 253 49-53.
53. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC & Jensen RA 1996 Growth retardation and tumour inhibition by BRCA1 (see comments). Nature Genetics 12 298-302.
54. Hurd C, Khattree N, Dinda S, Alban P & Moudgil VK 1997 Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene 15 991-995.
55. Isola JJ, Kallioniemi O-P, Chu LW, Fuqua SAW, Hilsenbeck SG, Osborne CK & Waldman FM 1995 Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. American Journal of Pathology 147 905-911.
56. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA & Weinberg RA 1992 Effects of an Rb mutation in the mouse (see comments). Nature 359 295-300.
57. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC & Rauscher F Jr 1998 BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 16 1097-1112.
58. Jost CA, Marin MC & Kaelin WG Jr 1997 p73 is a human p53-related protein that can induce apoptosis (see comments). Nature 389 191-194.
59. Kaelin WG Jr 1998 Another p53 Doppelganger? Science 281 57-58.
60. Kallioniemi A, Kallioniemi OP, Sudar D, Rutoviz D, Gray JW, Waldman F & Pinkel D 1992 Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258 818-821.
61. Kasami M, Vnencak-Jones CL, Manning S, Dupont WD & Page DL 1997 Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy. American Journal of Pathology 150 1925-1932.
62. Kashiwaba M, Tamura G & Ishida M 1994 Aberrations of the APC gene in primary breast carcinoma. Journal of Cancer Research and Clinical Oncology 120 727-731.
63. Kennedy D, Ramsdale T, Mattick J & Little M 1996 An RNA recognition motif in Wilms' tumor protein (WT1) revealed by structural modelling. Nature Genetics 12 329-332.
64. Kerangueven F, Essioux L, Dib A, Noguchi T, Allione F, Geneix J, Longy M, Lidereau R, Eisinger F, Pebusque MJ et al. 1995 Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene 10 1023-1026.
65. Kinzler KW & Vogelstein B 1997 Gatekeepers and caretakers. Nature 386 761-763.
66. Kinzler KW, Nilbert MC, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hamilton SR, Hedge P, Markham A et al. 1991 Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers (see comments). Science 251 1366-1370.
67. Knudson AG 1971 Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences of the USA 68 820-823.
68. Laake K, Odegard A, Andersen TI, Bukholm IK, Karesen R, Nesland JM, Ottestad L, Shiloh Y & Borresen-Dale AL 1997 Loss of heterozygosity at 11q23.1 in breast carcinomas: indication for involvement of a gene distal and close to ATM. Genes, Chromosomes and Cancer 18 175-180.
69. Lakhani SR, Collins N, Stratton MR & Sloane JP 1995 Atypical ductal hyperplasia of the breast: clonal proliferation with loss of heterzygosity on chromosomes. Journal of Clinical Pathology 48 611-615.
70. Lakhani SR, Slack DN, Hamoudi RA, Collins N, Stratton MR & Sloane JP 1996 Detection of allelic imbalance indicates that a proportion of mammary hyperplasia of usual type are clonal, neoplastic proliferations. Laboratory Investigations 74 129-135.
71. Lamb P & Crawford L 1986 Characterization of the human p53 gene. Molecular and Cellular Biology 6 1379-1385.
72. Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR & Futreal PA 1996 BRCA2 mutations in primary breast and ovarian cancers. Nature Genetics 13 238-240.
73. Lane DP & Crawford LV 1979 T antigen is bound to a host protein in SV40-transformed cells. Nature 278 261-263.
74. Lane DP, Lu X, Hupp T & Hall PA 1994 The role of the p53 protein in the apoptotic response. Philosophical Transactions of the Royal Society of London Series B. Biological Sciences 345 277-280.
75. Larsson SH, Charlieu JP, Miyagawa K, Engelkamp D, Rassoulzadegan M, Ross A, Cuzin F, van Heyningen V & Hastie ND 1995 Subnuclear localization of WT1 in splicing or transcription factor domains is regulated by alternative splicing. Cell 81 391-401.
76. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al. 1993 Identification of the von Hippel-Lindau disease tumor suppressor gene (see comments). Science 260 1317-1320.
77. Lee AV & Yee D 1995 Insulin-like growth factors and breast cancer. Biomedicine and Pharmacotherapy 49 415-421.
78. Lee EY, To H, Shew JY, Bookstein R, Scully P & Lee WH 1988 Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science 241 218-221.
79. Lee EY, Chang CY, Hu N, Wang YC, Lai CC, Herrup K, Lee WH & Bradley A 1992 Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis (see comments). Nature 359 288-294.
80. Lee WH, Bookstein R, Hong F, Young LJ, Shew JY & Lee EY 1987a Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235 1394-1399.
81. Lee WH, Shew JY, Hong FD, Sery TW, Donoso LA, Young LJ, Bookstein R & Lee EY 1987b The retinoblastoma susceptibility gene encodes a nuclear phosphoprotein associated with DNA binding activity. Nature 329 642-645.
82. Levine AJ 1997 p53, the cellular gatekeeper for growth and division. Cell 88 323-331.
83. Li FP & Fraumeni JF Jr 1969 Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Annals of Internal Medicine 71 747-752.
84. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH & Parsons R 1997 PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer (see comments). Science 275 1943-1947.
85. Lloyd KM & Dennis M 1963 Cowden's disease: a possible new symptom complex with multiple system involvement. Annals of Internal Medicine 58 136-142.
86. Lowe SW, Schmitt EM, Smith SW, Osborne BA & Jacks T 1993 p53 is required for radiation-induced apoptosis in mouse thymocytes (see comments). Nature 362 847-849.
87. Ludwig T, Chapman DL, Papaioannou VE & Efstratiadis A 1997 Targeted mutations of breast cancer susceptibility gene homologs in mice: lethal phenotypes of Brca1, Brca2, Brca1/ Brca2, Brca1/p53, and Brca2/p53 nullizygous embryos. Genes and Development 11 1226-1241.
88. Lynch ED, Ostermeyer EA, Lee MK, Arena JF, Ji H, Dann J, Swisshelm K, Suchard D, MacLeod PM, Kvinnsland S, Gjertsen BT, Heimdal K, Lubs H, Moller P & King MC 1997 Inherited mutations in PTEN that are associated with breast cancer, Cowden disease, and juvenile polyposis. American Journal of Human Genetics 61 1254-1260.
89. McBride OW, Merry D & Givol D 1986 The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proceedings of the National Academy of Sciences of the USA 83 130-134.
90. Maher ER, Bentley E, Yates JR, Barton D, Jennings A, Fellows IW, Ponder MA, Ponder BA, Benjamin C, Harris R et al. 1990a Mapping of von Hippel-Lindau disease to chromosome 3p confirmed by genetic linkage analysis. Journal of the Neurological Sciences 100 27-30.
91. Maher ER, Yates JR, Harries R, Benjamin C, Harris R, Moore AT & Ferguson-Smith MA 1990b Clinical features and natural history of von Hippel-Lindau disease (see comments). Quarterly Journal of Medicine 77 1151-1163.
92. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA et al. 1990 Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms (see comments). Science 250 1233-1238.
93. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL & Chodosh LA 1995 The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nature Genetics 11 17-26.
94. Matlashewski G, Lamb P, Pim D, Peacock J, Crawford L & Benchimol S 1984 Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO Journal 3 3257-3262.
95. Medeiros AC, Nagai MA, Neto MM & Brentani RR 1994 Loss of heterozygosity affecting the APC and MCC genetic loci in patients with primary breast carcinomas. Cancer Epidemiology, Biomarkers and Prevention 3 331-333.
96. Mihara K, Cao XR, Yen A, Chandler S, Driscoll B, Murphree AL, T'Ang A & Fung YK 1989 Cell cycle-dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 246 1300-1303.
97. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W et al. 1994 A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 66-71.
98. Miki Y, Katagiri T, Kasumi F, Yoshimoto T & Nakamura Y 1996 Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genetics 13 245-247.
99. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V & Koeffler HP 1986 Human p53 gene localized to short arm of chromosome 17. Nature 319 783-784.
100. Miyashita T & Reed JC 1995 Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 293-299.
101. Mizuta R, LaSalle JM, Cheng HL, Shinohara A, Ogawa H, Copeland N, Jenkins NA, Lalande M & Alt FW 1997 RAB22 and RAB163/mouse BRCA2: proteins that specifically interact with the RAD51 protein. Proceedings of the National Academy of Sciences of the USA 94 6927-6932.
102. Moll UM, Riou G & Levine AJ 1992 Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proceedings of the National Academy of Sciences of the USA 89 7262-7266.
103. Momand J, Zambetti GP, Olson DC, George D & Levine AJ 1992 The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69 1237-1245.
104. Nelen MR, Padberg GW, Peeters EA, Lin AY, van den Helm B, Frants RR, Coulon V, Goldstein AM, van Reen MM, Easton DF, Eeles RA, Hodgsen S, Mulvihill JJ, Murday VA, Tucker MA, Mariman EC, Starink TM, Ponder BA, Ropers HH, Kremer H, Longy M & Eng C 1996 Localization of the gene for Cowden disease to chromosome 10q22-23. Nature Genetics 13 114-116.
105. Nishizaki T, DeVries S, Chew K, Goodson WHI, Ljung BM, Thor A & Waldman FM 1997 Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes, Chromosomes and Cancer 19 267-272.
106. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK & Allred DC 1994 Molecular genetic studies of early breast cancer evolution by LOH. Breast Cancer Research and Treatment 32 5-12.
107. O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Clark GM & Allred DC 1998 Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. Journal of the National Cancer Institute 90 697-703.
108. Okamoto K & Beach D 1994 Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO Journal 13 4816-4822.
109. Ozbun MA & Butel JS 1995 Tumor suppressor p53 mutations and breast cancer: a critical analysis. Advances in Cancer Research 66 71-141.
110. Page DL, Dupont WD, Rogers LW & Rados MS 1985 Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 55 2698-2708.
111. Papa S, Seripa D, Merla G, Gravina C, Giai M, Sismondi P, Rinaldi M, Serra A, Saglio G & Fazio VM 1998 Identification of a possible somatic BRCA1 mutation affecting translation efficiency in an early-onset sporadic breast cancer patient. Journal of the National Cancer Institute 90 1011-1012.
112. Pecker I, Avraham KB, Gilbert DJ, Savitsky K, Rotman G, Harnik R, Fukao T, Schrock E, Hirotsune S, Tagle DA, Collins FS, Wynshaw-Boris A, Ried T, Copeland NG, Jenkins NA, Shiloh Y & Ziv Y 1996 Identification and chromosomal localization of Atm, the mouse homolog of the ataxia-telangiectasia gene. Genomics 35 39-45.
113. Pritchard-Jones K 1997 Molecular genetic pathways to Wilms tumor. Critical Reviews in Oncogenesis 8 1-27.
114. Raap AK 1998 Advances in fluorescence in situ hybridization. Mutational Research 400 287-298.
115. Rauscher FJD 1993 The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB Journal 7 896-903.
116. Rhei E, Kang L, Bogomolniy F, Federici MG, Borgen PI & Boyd J 1997 Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Research 57 3657-3659.
117. Rice JC, Massey-Brown KS & Futscher BW 1998 Aberrant methy lation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 17 1807-1812.
118. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A & te Riele H 1998 p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes and Development 12 1599-1609.
119. Romagnolo D, Annab LA, Thompson TE, Risinger JI, Terry LA, Barrett JC & Afshari CA 1998 Estrogen upregulation of BRCA1 expression with no effect on localization. Molecular Carcinogenesis 22 102-109.
120. Rosenberg CL, de las Morenas A, Huang K, Cupples LA, Faller DV & Larson PS 1996 Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. Journal of Clinical Investigations 98 1095-1100.
121. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S et al. 1995a A single ataxia telangiectasia gene with a product similar to PI-3 kinase (see comments). Science 268 1749-1753.
122. Savitsky K, Sfez S, Tagle DA, Ziv Y, Sartiel A, Collins FS, Shiloh Y & Rotman G 1995b The complete sequence of the coding region of the ATM gene reveals similarity to cell cycle regulators in different species. Human Molecular Genetics 4 2025-2032.
123. Schena M, Shalon D, Davis RW & Brown PO 1995 Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270 467-470.
124. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J & Livingston DM 1997a Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 90 425-435.
125. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T & Livingston DM 1997b Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell 88 265-275.
126. Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor-Krakauer D et al. 1988 Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332 268-269.
127. Serrano M 1997 The tumor suppressor protein p16INK4a. Experimental Cell Research 237 7-13.
128. Sharan SK, Morimatsu M, Albrecht U, Lim DS, Regel E, Dinh C, Sands A, Eichele G, Hasty P & Bradley A 1997 Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2 (see comments). Nature 386 804-810.
129. Shattuck-Eidens D, Oliphant A, McClure M, McBride C, Gupte J, Rubano T, Pruss D, Tavtigian SV, Teng DH, Adey N, Staebell M, Gumpper K, Lundstrom R, Hulick M, Kelly M, Holmen J, Lingenfelter B, Manley S, Fujimura F, Luce M, Ward B, Cannon-Albright L, Steele L, Offit K, Thomas A et al. 1997 BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing (see comments). Journal of the American Medical Association 278 1242-1250.
130. Shieh S-Y, Ikeda M, Taya Y & Prives C 1997 DNA-damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91 325-334.
131. Shiloh Y 1995 Ataxia-telangiectasia: closer to unraveling the mystery. European Journal of Human Genetics 3 116-138.
132. Silberstein GB, Van Horn K, Strickland P, Roberts CT Jr & Daniel CW 1997 Altered expression of the WT1 Wilms tumor suppressor gene in human breast cancer. Proceedings of the National Academy of Sciences of the USA 94 8132-8137.
133. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR & Liotta JR 1998 Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends in Genetics 14 272-276.
134. Singh B, Ittmann MM & Krolewski JJ 1998 Sporadic breast cancers exhibit loss of heterozygosity on chromosome segment 10q23 close to the Cowden disease locus. Genes, Chromosomes and Cancer 21 166-171.
135. Slansky JE & Farnham PJ 1996 Introduction to the E2F family: protein structure and gene regulation. Current Topics in Microbiology and Immunology 208 1-30.
136. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB, O'Connor PM & Fornace AJ Jr 1994 Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen (see comments). Science 266 1376-1380.
137. Southern EM 1996 DNA chips: analysing sequence by hybridization to oligonucleotides on a large scale. Trends in Genetics 12 110-115.
138. Stirzaker C, Millar DS, Paul CL, Warnecke PM, Harrison J, Vincent PC, Frommer M & Clark SJ 1997 Extensive DNA methylation spanning the Rb promoter in retinoblastoma tumors. Cancer Research 57 2229-2237.
139. Storey A, Thomas M, Kalita A, Harwood C, Gardiol D, Mantovani F, Breuer J, Leigh IM, Matlashewski G & Banks L 1998 Role of a p53 polymorphism in the development of human papillomavirus-associated cancer (see comments). Nature 393 229-234.
140. Swift M, Morrell D, Massey RB & Chase CL 1991 Incidence of cancer in 161 families affected by ataxia-telangiectasia (see comments). New England Journal of Medicine 325 1831-1836.
141. T'Ang A, Varley JM, Chakraborty S, Murphree AL & Fung YK 1988 Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science 242 263-266.
142. Takahashi K & Suzuki K 1994 DNA synthesis-associated nuclear exclusion of p53 in normal human breast epithelial cells in culture. Oncogene 9 183-188.
143. Tavtigian SV, Simard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, Merajver S, Thorlacius S, Offit K, Stoppa-Lyonnet D, Belanger C, Bell R, Berry S, Bogden R, Chen Q, Davis T, Dumont M, Frye C, Hattier T, Jammulapati S, Janecki T, Jiang P, Kehrer R, Leblanc JF, Goldgar DE et al. 1996 The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds (see comments). Nature Genetics 12 333-337.
144. Tavtigian SV, Thomas A, Frank TS & Skolnick MH 1998 The BRCA1 gene and its protein product: characterization, therapeutic and diagnostic implications. Advances in Oncology 14 3-13.
145. Thompson AM, Morris RG, Wallace M, Wyllie AH, Steel CM & Carter DC 1993 Allele loss from 5q21 (APC/MCC)and 18q21 (DCC) and DCC mRNA expression in breast cancer. British Journal of Cancer 68 64-68.
146. Tirkkonen M, Tanner M, Karhu R, Kallioniemi A, Isola J & Kallioniemi OP 1998 Molecular cytogenetics of primary breast cancer by CGH. Genes, Chromosomes and Cancer 21 177-184.
147. Tsou HC, Ping XL, Xie XX, Gruener AC, Zhang H, Nini R, Swisshelm K, Sybert V, Diamond TM, Sutphen R & Peacocke M 1998 The genetic basis of Cowden's syndrome: three novel mutations in PTEN/MMAC1/TEP1. Human Genetics 102 467-473.
148. Ueda K, Nishijima M, Inui H, Watatani M, Yayoi E, Okamura J, Yasutomi M, Nakamura Y & Miyoshi Y 1998 Infrequent mutations in the PTEN/MMAC1 gene among primary breast cancers. Japanese Journal of Cancer Research 89 17-21.
149. Wang Z-Y, Qui Q-Q & Deuel TF 1993 The Wilms' tumor gene product WT1 activates or suppresses transcription through separate functional domains. Journal of Biological Chemistry 268 9172-9175.
150. Watts CK, Brady A, Sarcevic B, deFazio A, Musgrove EA & Sutherland RL 1995 Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Molecular Endocrinology 9 1804-1813.
151. Woo RA, McLure KG, Lees-Miller SP, Rancourt DE & Lee PWK 1998 DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. Nature 394 700-705.
152. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C & Micklem G 1995 Identification of the breast cancer susceptibility gene BRCA2 (see comments) (published erratum appears in Nature 1996 379 749). Nature 378 789-792.
153. Yunis JJ & Ramsay N 1978 Retinoblastoma and subband deletion of chromosome 13. American Journal of Diseases of Children 132 161-163.
154. Zakut-Houri R, Bienz-Tadmor B, Givol D & Oren M 1985 Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO Journal 4 1251-1255.
155. Zambetti G & Le vine A 1993 A comparison of biological activities of wildtype and mutant p53. FASEB Journal 7 855-865.